NEW YORK, Aug. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in iRobot Corporation ("iRobot Corporation" or the "Company") (NASDAQ: IRBT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of iRobot Corporation investors who were adversely affected by alleged securities fraud between January 29, 2024 and March 11, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/irobot-co ...

Core Viewpoint - Neogen Corporation is facing a class action securities lawsuit due to alleged securities fraud that misled investors regarding the integration with 3M Company's Food Safety Division [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by misleading statements made between January 5, 2023, and June 3, 2025 [1]. - Defendants allegedly issued materially false statements about the integration's progress and downplayed inefficiencies that arose during the process [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 16, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4].

NEW YORK, Aug. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fiserv, Inc. ("Fiserv, Inc." or the "Company") (NYSE: FI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fiserv, Inc. investors who were adversely affected by alleged securities fraud between July 24, 2024 and July 22, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/fiserv-inc-lawsuit-submission-form? ...

Core Insights - Best Buy has launched a third-party marketplace, significantly expanding its product offerings and joining major retailers like Walmart and Amazon [2][3] - The marketplace, powered by Mirakl, allows Best Buy to integrate new products from various sellers, enhancing the shopping experience while maintaining brand alignment [2][4] Product Expansion - The new marketplace has more than doubled the available items at Best Buy, introducing hundreds of new brands and categories, including seasonal décor, automotive tech, and licensed sports merchandise [2][3] - Best Buy aims to fill gaps in its product lineup, such as offering furniture to complement large-screen TVs, and providing smaller vendors with a platform to sell their products [5] Market Context - The launch of the marketplace comes at a time when Best Buy is experiencing declining revenues, with projections for yearly revenue between $41.1 billion and $41.9 billion, which is below previous guidance [6][7] - Factors contributing to the revenue decline include a slow housing market, reduced consumer spending, and a decrease in tech purchases following the COVID-19 pandemic [6]

Core Viewpoint - J.M. Smucker Company is under investigation for potential violations of federal securities laws following significant impairment charges related to its Sweet Baked Snacks segment and the Hostess brand trademark, which have led to a substantial decline in stock price [1][3]. Group 1: Company Overview - J.M. Smucker manufactures and markets branded food and beverage products, including the recently acquired Hostess Brands, Inc., which specializes in sweet baked goods [2]. - The company previously claimed that the Hostess acquisition was "highly complementary" and that trends in sweet snacking were favorable [2]. Group 2: Financial Performance - In Q4 2025, J.M. Smucker reported an $867 million impairment charge related to the goodwill of its Sweet Baked Snacks segment and a $113 million impairment charge for the Hostess brand trademark due to underperformance [3]. - Following the announcement of these impairment charges, J.M. Smucker's stock price fell by $17.44 per share, or over 18%, from $111.85 on June 9, 2025, to $94.41 on June 10, 2025 [3].

Core Viewpoint - BellRing Brands, Inc. is under investigation for potential violations of federal securities laws, with concerns regarding the sustainability of its sales growth driven by temporary trade inventory loading rather than genuine consumer demand [1][2]. Group 1: Company Overview - BellRing Brands operates in the convenient nutrition category, primarily known for its brands Premier Protein and Dymatize, which offer ready-to-drink protein shakes and powders [2]. - The company reported that Premier Protein achieved an all-time high in household penetration and strong demand across all channels, attributed to distribution expansion and promotional activities [2]. Group 2: Sales Growth Concerns - The sales growth during the relevant period may not be sustainable, as it could have been influenced by temporary trade inventory loading at key retailers [2]. - On May 5, 2025, BellRing disclosed that several key retailers reduced their weeks of supply, which would negatively impact growth in Q3 2025 [3]. Group 3: Stock Performance - Following the May 5 announcement, BellRing's stock price dropped by $13.96, or over 18%, from $77.34 to $63.38 per share [3]. - On August 4, 2025, the company reported disappointing quarterly consumption of Premier Protein RTD Shakes, leading to a further decline in stock price by $17.46, or nearly 33%, from $53.64 to $36.18 per share [4].

Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Financial Guidance and Performance - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions showed lower than expected enrollment growth and increased morbidity rates in the majority of the states Centene serves [4]. Stock Market Reaction - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report revealed lower than expected market growth and higher morbidity rates, leading to a significant stock price drop of $22.87 per share, or over 40%, from $56.65 to $33.78 [5].

Core Viewpoint - A lawsuit has been filed against Flywire Corporation and its senior executives for potential violations of federal securities laws, with claims related to the company's alleged misrepresentation of its revenue growth and the impact of visa-related restrictions on its business [1][2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Eastern District of New York, titled Hickman v. Flywire Corp., et al., No. 1:25-cv-04110 [2]. - Investors have until September 23, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - Flywire operates as a payments-enablement and software company, primarily serving the education sector, which relies heavily on international student enrollments [3]. - The company has faced challenges due to tightening student visa and permitting rules implemented by the Canadian and Australian governments in late 2023 and early 2024 [3]. Group 3: Allegations and Impact - The lawsuit alleges that Flywire overstated the strength and sustainability of its revenue growth while downplaying the negative impacts of permit- and visa-related restrictions [4]. - On February 25, 2025, Flywire disclosed a significant deterioration in its education sector business, citing "double digit declines in student visa issuance" and anticipated continued restrictions [5]. - Following this announcement, Flywire's stock price fell approximately 37%, from $17.64 per share to $11.05 per share within a day [5].

Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and certain senior executives for potential violations of federal securities laws, particularly concerning the safety claims of their product Elevidys [1][2][3]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, with Elevidys being its most significant product aimed at treating Duchenne muscular dystrophy [3]. Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Southern District of New York, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Sarepta securities [2]. - Investors have until August 25, 2025, to request to be appointed to lead the case [2]. Product Safety Concerns - Sarepta allegedly misrepresented the safety profile of Elevidys, claiming that its benefits outweighed the risks, while in reality, the treatment has been linked to fatal acute liver failure in some patients [3]. Stock Performance - Following the announcement of a patient's death due to acute liver failure on March 18, 2025, Sarepta's stock price dropped by $27.81, or over 27%, from $101.35 to $73.54 per share [4]. - A second death announcement on June 15, 2025, led to a further decline of $15.24, or more than 42%, from $36.18 to $20.94 per share [4]. - A third death related to Elevidys was reported on July 17, 2025, resulting in a stock price drop of over 40% on July 18, 2025 [5].

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following issues related to its acquisition of Pro-ficiency Holdings, Inc. and subsequent financial reporting problems [1][2][3]. Group 1: Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. - In June 2024, Simulations Plus acquired Pro-ficiency Holdings, which was expected to enhance its market reach and sales [2][3]. Group 2: Financial Reporting Issues - The company claimed that the integration of Pro-ficiency would double its total addressable market and significantly contribute to sales, but it appears that the integration was not successful and internal controls were ineffective [3]. - On April 15, 2025, Simulations Plus appointed Grant Thornton LLP as its new auditor, but shortly after, it reported disappointing preliminary financial results for Q3 2025, attributing the decline to market uncertainties [4]. Group 3: Stock Performance - Following the announcement of disappointing financial results on June 11, 2025, Simulations Plus's stock price dropped by $6.39, or over 24%, from $26.44 to $20.05 per share [4]. - On July 14, 2025, the company reported a $77.2 million charge related to prior acquisitions and dismissed Grant Thornton, which raised concerns about its internal controls and financial reporting [5]. - The stock price fell again by $4.50, nearly 26%, from $17.47 to $12.97 per share after the news of the impairment charge and auditor dismissal [5].